WF10: Phase II start

This month, Nuvo will begin the double-blind, placebo-controlled, Canadian Phase II 2015 WF10 Trial to evaluate 0.5 mL/kg IV WF10 once daily for 5 days in about 146 patients with moderate to severe al...